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Abstract
Introduction: The objectives of this study were to determine small arterial elasticity (SAE) in systemic lupus
erythematosus (SLE) and to investigate its relationship with intima media thickness (IMT), accumulation of
advanced glycation end products (AGEs), endothelial activation and inflammation.
Methods: Thirty SLE patients with inactive disease and 30 age- and sex-matched healthy controls were included.
Twenty patients with essential hypertension (EH) served as positive control. SAE was assessed by pulse-wave
analysis using tonometric recordings of the radial artery. IMT of the carotid arteries was measured by ultrasound.
AGE accumulation was assessed with an AGE-reader. Endothelial activation markers and C-reactive protein (CRP)
were determined by enzyme-linked immunosorbent assay (ELISA).
Results: SAE was decreased in SLE (P = 0.01) and further decreased in EH (P < 0.01) compared to healthy controls.
IMT was increased in EH (P < 0.05), but not in SLE. AGE accumulation was increased in SLE (P < 0.05) and further
increased in EH (P < 0.01) compared to healthy controls. Endothelial activation markers and CRP were increased in
SLE but not in EH. SAE related to AGE accumulation (r = -0.370, P < 0.05), CRP (r = -0.429, P < 0.05) and creatinine
clearance (r = 0.440, P < 0.05), but not to IMT and endothelial activation markers. In multivariate analysis SLE was
an independent predictor of SAE.
Conclusions: SAE is decreased in SLE patients without increased IMT, independently of traditional cardiovascular
risk factors. Longitudinal studies are needed to investigate whether SAE, endothelial activation and AGE
accumulation are early markers for cardiovascular disease in SLE.
Introduction
Systemic lupus erythematosus (SLE) is associated with an
increased prevalence of cardiovascular disease (CVD), due
to accelerated atherosclerosis [1,2]. Traditional cardiovas-
cular risk factors cannot fully explain the presence of
accelerated atherosclerosis in these patients, suggesting
that other factors are involved [3-5]. A potential non-
traditional risk factor in these patients is formation and
accumulation of advanced glycation end products (AGEs).
We previously showed that accumulation of AGEs is
increased in SLE patients and that AGE accumulation is
related to intima media thickness (IMT), a surrogate mar-
ker for atherosclerosis [6].
Endothelial cell (EC) activation and dysfunction are
among the first steps in atherogenesis [7]. Detection of
these early and reversible events may be of clinical rele-
vance, because it offers the possibility to intervene early
in the process leading to atherosclerosis. The presence
of EC activation can be assessed by measuring circulat-
ing levels of soluble vascular cell adhesion molecule-1
(VCAM-1), thrombomodulin (TM), and von Willebrand
factor (vWf). EC dysfunction can be detected by several
techniques of which flow mediated vasodilatation (FMD)
is most commonly used. Another technique is pulse
wave analysis (PWA) which measures large and small
artery elasticity (LAE and SAE, respectively). SAE is
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hypertension, diabetes mellitus and chronic kidney dis-
ease [8-10]. SAE is inversely related to IMT and in a
retrospective study SAE was shown to be an indepen-
dent predictor of cardiovascular events [11,12].
Based on these observations we hypothesized that SAE
is decreased in SLE patients and that decreased SAE is
related to non-traditional risk factors, including AGEs.
For this reason, we determined artery elasticity in
patients with SLE and related artery elasticity to EC acti-
vation, intima media thickness and traditional and non-
traditional risk factors, including accumulation of AGEs.
Materials and methods
Subjects
Thirty consecutive patients (26 females, 4 males) fulfilling
the American College of Rheumatology criteria for SLE
[13], who attended the out-patient clinic of the University
Medical Center Groningen, were included (Table 1).
Aiming at markers for early detection of atherosclerosis,
patients with a history of CVD, including ischemic heart
disease (ICD-9 classification 410 to 414), cerebrovascular
accidents or peripheral vascular disease, were excluded.
Other exclusion criteria were pregnancy, diabetes melli-
tus, renal insufficiency (creatinine > 140 μmol/l) and
active disease, defined as SLE Disease Activity Index
(SLEDAI) > 4 [14]. Thirty age- and sex-matched healthy
subjects were recruited as negative controls and
20 patients with still untreated essential hypertension
(EH) were included as positive controls (Table 2). Hyper-
tension was defined as a systolic blood pressure = 140
mmHg and/or a diastolic blood pressure = 90 mmHg,
based on at least three measurements, and/or the use of
antihypertensive drugs. Possible secondary causes of
hypertension had to be excluded. The same exclusion
criteria as for SLE patients applied to EH patients. All
patients and controls were Caucasians, except for two
SLE patients of Asian origin. The local research ethics
committee gave approval for the study and written
informed consent was obtained from each participant.
All traditional cardiovascular risk factors were assessed.
Body mass index, smoking status, and family history of
CVD (considered positive if first-degree relatives suffered
from CVD before 60 years of age) were recorded. Dyslipi-
deamia was defined as plasma cholesterol above
5.0 mmol/L and/or plasma low density lipoprotein (LDL)
cholesterol above 3.0 mmol/L and/or triglycerides above
1.7 mmol/l and/or high density lipoprotein (HDL)
cholesterol below 1.2 mmol/L in women and below
1.0 mmol/L in men and/or use of lipid lowering drugs
[15]. Creatinine clearance was estimated using the Cock-
croft-Gault formula. Use of prednisolone, azathioprine,
and hydroxychloroquine was categorized as current and
none, and daily dose was recorded. All measurements
and blood sampling were performed after an overnight
fast to exclude postprandial effects.
Pulse-wave analysis
Arterial elasticity was assessed by pulse-wave analysis
using the CR-2000 (Hypertension Diagnostics, Eagan,
MN, USA). The CR-2000 records and analyses the
blood pressure waveform data from the Arterial Pulse
Pressure Sensor. SAE was estimated from a computer-
ized pulse contour analysis using a Windkessel model
[16]. Measurements were performed after 10 minutes of
acclimatization in a temperature controlled room (22°C)
with the subject in supine position. The arterial pulse
pressure sensor was placed over the right and subse-
quently over the left radial artery. A blood pressure cuff
was placed on the opposite arm to record blood pres-
sure (BP). The average of three readings of BP and SAE
of both the left and right arm were used for analysis.
To assess reproducibility of this technique, 10 subjects
of each group were studied by a single investigator on
two separate occasions, with three weeks interspace.
The intra-individual coefficient of variation was 11.2%
for SAE.
Table 1 Disease characteristics of SLE patients
SLE (n = 30)
ACR criteria, n (%)
Malar rash 13 (43%)
Discoid rash 6 (20%)
Photosensitivity 12 (40%)
Oral ulcers 9 (30%)
Arthritis 20 (66%)
Serositis 16 (53%)
Renal disorder 13 (43%)
Neurological disorder 1 (3%)
Hematological disorder 23 (77%)
Immunological disorder 26 (87%)
Antinuclear antibody 30 (100%)
Duration of disease, months 146 (49 to 209)
SLEDAI 4( 2t o4 )
Anti-dsDNA, Farr 20 (6 to 140)
Complement C3, g/l 0.89 (0.74 to 1.06)
Complement C4, g/l 0.12 (0.09 to 0.17)
C-reactive protein, mg/l 1.8 (0.5 to 4.5)
Creatinine Clearance, ml/min 106 (93 to 131)
Prednisolone use, n (%) 19 (63%)
Dose, mg/day 7.5 (5 to 10)
Hydroxychloroquine use, n (%) 15 (50%)
Dose, mg/dag 400 (400 to 400)
Azathioprine use, n (%) 11 (37%)
Dose, mg/day 100 (50 to 150)
Unless stated otherwise, data are expressed as median (25 to 75%). ACR,
American College of Rheumatology; SLEDAI, SLE disease activity index; anti-
dsDNA, anti-double stranded DNA.
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Tissue AGE accumulation was assessed as skin auto-
fluorescence (AF) on the ventral site of the lower arm
with the AGE-Reader (DiagnOptics BV, Groningen, The
Netherlands) [17]. In short, the AGE-Reader consists of
a tabletop box containing a black light excitation light
source (peak wavelength approximately 365 nm). Light
emitted from the skin is measured with an integrated
spectrometer. Measurement is fully automated and takes
approximately 30 seconds to perform, giving an average
value over 50 individual scans. The measurement was
performed at non-lesional skin. Skin AF is calculated by
dividing the mean value of the emitted light intensity
per nm between 420 and 600 nm by the mean value of
the excitation light intensity per nm between 300 and
420 nm, expressed as arbitrary units (AU). Repeated
measurements on one day in controls and diabetic
patients showed an overall Altman error percentage of
five percent [17].
Measurement of intima media thickness
Details of the method, as used in this study, have been
described by de Groot et al.[ 1 8 ] .I M Tw a sd e t e r m i n e d
at the common carotid artery (CCA), the bulb and the
internal carotid artery (ICA) at left and right sites using
an Acuson 128XP ultrasound system with 7 MHz linear
array transducers (Acuson Corp., Silicon Valley, Califor-
nia, USA). A B-mode image was obtained after which a
probe was positioned perpendicular to the far wall,
showing an intima-media complex over approximately
one centimeter. Mean IMT (the mean of the segment
studied) and the maximum IMT (the highest IMT value
found among the segment studied) were determined. As
endpoint we used the mean of the mean (mean IMT)
and the mean of the maximum (mean to max IMT) of
the far wall IMT of the six imaged carotid segments.
From studies on repeatability, the error of variation in
measurement is calculated as 0.03 mm for the carotid
far wall IMT.
Table 2 Traditional cardiovascular risk factors and vascular parameters of patients and healthy controls
CTL (n = 30) SLE (n = 30) EH (n = 20)
Age, years 42 ± 11 41 ± 10 49 ± 15
Female, n (%) 26 (87%) 26 (87%) 12 (60%)
BMI, kg/m
2 24 ± 2.6 25 ± 5.0 25 ± 3.7
Blood pressure, mmHg
Systolic 120 ± 9 125 ± 17 151 ± 15**
##
Diastolic 70 ± 6 72 ± 10 88 ± 9**
##
Dyslipidaemia, n (%) 14 (47%) 15 (50%) 13 (65%)
Smokers, n (%) 3 (10%) 9 (30%)* 3 (15%)#
Family history CVD, n 5 (17%) 5 (17%) 7 (35%)
HbA1c (%) 5.4 ± 0.3 5.7 ± 0.7 5.3 ± 0.4
Statins, n (%) 0 1 (3%) 3 (15%)*
Antihypertensives, n (%) 0 9 (30%)** 0
Beta-blockers 0 4 (13%)* 0
ACE inhibitors 0 5 (17%)* 0
Calcium antagonists 0 1 (3%) 0
Hypertension, n (%) 0 9 (30%)** 20 (100%)**
##
SAE, ml/mmHg × 100 8.1 ± 2.6 6.4 ± 2.7** 5.2 ± 3.8**
AF, AU 1.9 ± 0.4 2.1 ± 0.5* 2.3 ± 0.5**
IMT, mm
Mean Maximum 0.72 (0.69 to 0.87) 0.71 (0.68 to 0.77) 0.89 (0.76 to 0.99)*
##
Mean 0.64 (0.59 to 0.70) 0.61 (0.57 to 0.66) 0.75 (0.67 to 0.86)**
##
C-reactive protein, mg/l 0.8 (0.4 to 1.5) 1.8 (0.5 to 4.5)* 1.7 (0.5 to 2.8)
VCAM-1, ng/ml 371 ± 101 548 ± 165** 393 ± 111
##
vWf, % 67 (46 to 88) 130 (89 to 223)** 78 (50 to 177)
#
TM, ng/ml 1.6 (1.2 to 1.7) 1.7 (1.2 to 2.3) 1.8 (1.5 to 2.6)*
Unless stated otherwise, data are expressed as mean ± standard deviation when normally distributed and as median (interquartile range) when non-normally
distributed. ACE, angiotensin converting enzyme; AF, autofluorescence; AU, arbitrary units; BMI, body mass index; CrCl, creatinine clearance; CRP, C-reactive
protein; CTL, healthy controls; CVD, cardiovascular disease; EH, essential hypertension patients; HbA1c, hemoglobulin A1c; IMT, intima media thickness; SAE, small
artery elasticity; SLE, SLE patients; TM, thrombomodulin; VCAM-1, vascular cell adhesion molecule-1; vWf, von Willebrand factor. Patients versus controls:
* P ≤ 0.05, ** P ≤ 0.01. EH patients versus SLE patients:
# P ≤ 0.05,
## P ≤ 0.01.
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Fasting cholesterol, HDL, LDL, triglycerides, creatinine,
glycated haemoglobin (HbA1c) and C-reactive protein
(CRP) levels were measured by routine techniques. In
patients, levels of complement C3 and C4 were measured
by nephelometry, and levels of antibodies to double
stranded DNA (dsDNA) by 125I Farr assay. Additionally,
serum and plasma samples were stored at -20°C for deter-
mination of levels of markers of EC activation. Serum
levels of vascular cell adhesion molecule-1 (VCAM-1)
(R&D Systems, Abingdon, UK) and thrombomodulin
(TM) (Diaclone, Besancon, France) were measured
according to the manufacturer’s instructions. Levels of von
Willebrand factor (vWf) were determined using an in-
house ELISA as described [19].
Statistical methods
Power analysis revealed that 30 subjects in each group
h a dt ob ei n c l u d e dt od e t e c tad i f f e r e n c ei nS A Eo f
2.0 ml/mmHg × 100 with a standard deviation of 2.8 at
a significance level of 0.05 with a power of 80%.
Except when stated otherwise, values are expressed as
mean ± standard deviation when normally distributed
and as median (interquartile range) when non-normally
distributed. Comparisons between groups were made by
Mann-Whitney tests or two-sample t-test for continuous
variables and by chi-square analysis for categorical vari-
ables. Univariate correlations were assessed by Pearson’s
correlation coefficient, when variables were normally dis-
tributed. Otherwise, Spearman’s correlation coefficient
was used.
To assess influence of traditional cardiovascular risk
factors on SAE, univariate linear regression and multi-
variate linear regression with backward inclusion of vari-
ables was performed. Variables that had a P-value < 0.05
in univariate analysis together with variables that signifi-
cantly differed between healthy controls and SLE
patients were included in the model. The probability of
F for removal was 0.10.
All analyses were performed using SPSS 16.0 (SPSS
Inc., Chicago, IL, USA). A two-sided P-value < 0.05 was
considered to indicate statistical significance.
Results
Characteristics of patients and controls
Characteristics of patients and age- and sex-matched
controls are presented in Tables 1 and 2. Concerning tra-
ditional cardiovascular risk factors, more SLE patients
were smoking compared to healthy controls (30% vs 10%,
respectively) and SLE patients more often used antihy-
pertensive drugs compared to healthy controls (30% vs
0%, respectively). Patients with essential hypertension
had increased diastolic and systolic blood pressure and
more often used statins compared to healthy controls.
Small Artery Elasticity
SAE was decreased in SLE patients (P =0 . 0 1 )a n dE H
patients (P < 0.01) compared to healthy controls (Table 2).
Since the increased prevalence of hypertension and smok-
ing among SLE patients could have influenced results, we
reanalysed data after exclusion of subject with hyperten-
sion and smokers. After exclusion of both subjects with
hypertension and smokers, SAE remained significantly
decreased in SLE patients (n = 14) compared to controls
(n = 27, P = 0.021).
Intima media thickness
Mean to max IMT and mean IMT did not differ
between SLE patients and healthy controls, whereas
both the mean to max IMT and mean IMT were
increased in EH patients compared to healthy controls
(P < 0.05 and P = 0.01, respectively) (Table 2).
Accumulation of advanced glycation end products
AGE accumulation was increased in SLE patients (P =
0.02) and in EH patients (P <0 . 0 0 1 )c o m p a r e dt o
healthy controls (Table 2).
Markers of EC activation and inflammation
Markers of EC activation are presented in Table 2.
Levels of vWf and sVCAM-1 were elevated in SLE
patients compared to healthy controls (P < 0.001 and
P < 0.001, respectively) but not in EH patients. Levels of
TM did not differ between SLE patients and healthy
controls, whereas levels of TM were increased in EH
patients compared to healthy controls (P =0 . 0 4 ) .L e v e l s
o fC R Pw e r ei n c r e a s e di nS L Ep a t i e n t s( P <0 . 0 5 )b u t
not in EH patients.
Influence of traditional cardiovascular riskfactors on SAE
Univariate and multivariate analysis was performed to
assess whether the difference in SAE between SLE
patients and healthy controls could be explained by tra-
ditional cardiovascular risk factors. Factors that related
to SAE in univariate analysis and factors that signifi-
cantly differed between SLE patients and healthy con-
trols (Table 2) were included in multivariate analysis.
This analysis revealed that age, gender, smoking, and
SLE are independently associated with SAE (Table 3). In
addition, we assessed whether SAE and other vascular
parameters differed between SLE patients with and SLE
patients without hypertension, no significant differences
were found (Table 4).
Relations between SAE, IMT, AGE accumulation and
disease related factors
Univariate analysis performed on data of SLE patients and
healthy controls together revealed inverse correlations
between SAE and AGE accumulation (r = -0.336,
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clearance (r = 0.376, P = 0.004). In SLE patients, SAE
inversely correlated to AGE accumulation (r = -0.370, P =
0.044). Concerning disease related factors, SAE was posi-
tively correlated to creatinine clearance (r = 0.440, P =
0.017) and inversely correlated to CRP (r = -0.429, P =
0.025). No significant correlations were found between
SAE and IMT.
Discussion
In searching for early markers for atherosclerosis we eval-
uated SAE in relation to EC activation, inflammation,
intima media thickness and accumulation of AGEs in
patients with SLE without overt CVD and related our find-
ings to patients at risk for premature atherosclerosis,
which are those with untreated essential hypertension
(EH).
First, we found that SAE is decreased in SLE patients
as was the case in our positive control group consisting
of EH patients. More importantly and in contrast to EH
patients, this decrease was found in SLE patients with
EC activation but without increased IMT and could not
be explained by the presence of traditional cardiovascu-
lar risk factors. Second, we confirmed our previous find-
ing that AGE accumulation is increased in SLE patients
[ 6 ]a n df o u n dt h a tA G Ea c c u m u l a t i o ni si n v e r s e l y
related to SAE.
In contrast to others [20], we assessed SAE in patients
without overt cardiovascular disease. In accordance with
the latter, IMT was not increased in our SLE patients,
supporting the assumption that SAE is an early marker
of atherosclerosis. SAE might reflect EC function.
Several studies have reported a correlation between SAE
and flow-mediated vasodilatation (FMD), the traditional
Table 3 Univariate and multivariate linear regression analysis for SAE in SLE patients and healthy controls (CTL)
Univariate analysis Multivariate analysis (R
2 = 0.524)
B (95% CI) P-value B (95% CI) P-value
Age (yr) -0.119 (-0.182 to -0.056) < 0.001 -0.126 (-0.178 to 0.074) < 0.001
Gender
a -2.357 (-4.392 to -0.323) 0.024 -2.067 (-3.656 to -0.477) 0.012
BMI (kg/m2) 0.092 (-0.094 to -0.278) 0.324 **
Blood pressure (mmHg)
Systolic -0.019 (-0.073 to 0.035) 0.486 **
Diastolic -0.065 (-0.154 to 0.024) 0.151 **
Antihypertensives use
b 0.201 (-1.636 to 2.037) 0.828 *
Dyslipidaemia
c -0.645 (-2.106 to 0.816) 0.381 **
Smoking
d -2.542 (-4.240 to -0.844) 0.004 -2.186 (-3.589 to -0.782) 0.003
Family history CVD
e 0.667 (-1.285 to 2.619) 0.497 **
HbA1c -0.597 (-2.895 to 1.702) 0.596 **
SLE or CTL
f -0.916 (-1552 to -0.279) 0.005 -1.425 (-2.549 to - 0.301) 0.014
B refers to influence on SAE.
* Variable was not selected during multivariate regression analysis.
**Variable was not tested in multivariate regression analysis because of a P-value > 0.05 in univariate regression analysis and/or no significant difference between
between healthy controls and SLE patients.
a: male were defined as 0, female as 1,
b: non-hypertensive subjects were defined as 0, hypertentive subjects as 1,
c: no dyslipidaemia was defined as 0,
dyslipidaemia as 1,
d: non-smokers were defined as 0, smokers as 1,
e: negative family history was defined as 0, positive family as 1,
f: healthy controls were
defined as 0, SLE patients were defined as 1.
Table 4 Differences in vascular parameters between SLE patients with and without hypertension
CTL (n = 0) SLE - hypertension
(n = 21)
SLE + hypertension
(n =9 )
SAE, ml/mmHg × 100 8.1 ± 2.6 6.4 ± 2.1* 6.4 ± 4.0
AF, AU 1.9 ± 0.4 2.1 ± 0.5* 2.2 ± 0.6
IMT, mm
Mean Maximum 0.72 (0.69 to 0.87) 0.70 (0.68 to 0.76) 0.73 (0.60 to 0.98)
Mean 0.64 (0.59 to 0.70) 0.61 (0.58 to 0.65) 0.62 (0.55 to 0.81)
VCAM-1, ng/ml 371 ± 101 534 ± 159** 578 ± 182**
vWf, % 67 (46 to 88) 123 (89 to 189)** 156 (83 to 397)**
TM, ng/ml 1.6 (1.2 to 1.7) 1.8 (1.4 to 2.6) 1.3 (0.6 to 1.8)
Unless stated otherwise, data are expressed as mean ± standard deviation when normally distributed and as median (interquartile range) when non-normally
distributed. AF, autofluorescence; AU, arbitrary units; CTL, healthy controls; MT, intima media thickness; SAE, small artery elasticity; SLE, SLE patients; TM,
thrombomodulin; VCAM-1, vascular cell adhesion molecule-1; vWf, von Willebrand factor. Patients versus controls: * P ≤ 0.05, ** P ≤ 0.01. There were no
significant differences between SLE patients without hypertension and SLE patients with hypertension.
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with other studies showing EC dysfunction in patients
with SLE using FMD [22,23]. Although FMD is a useful
research tool to assess endothelial function, its poor
reproducibility and its demands on the examiner and
subjects limit the use of FMD in clinical practice [24].
PWA is well-tolerated and requires less time and experi-
ence of the examiner. We showed that reproducibility of
this technique is acceptable, especially when natural var-
iation in blood pressure (CV: 4.8% for systolic BP and
5.7% for diastolic BP), which is related to vascular func-
tion, is taken into account. In addition, van Doornum
et al. showed that SAE is a more sensitive measure of
vascular dysfunction than FMD in rheumatoid arthritis
(RA) [21].
However, whether SAE is solely a measure of EC
function is questionable. Besides EC function, functional
and structural changes are likely to be determinants of
artery elasticity as well. Duprez et al.showed that SAE is
inversely related to IMT, suggesting that IMT is a deter-
minant of SAE or visa-versa [11]. Although the physio-
logical meaning of Windkessel-derived elasticity values
remains unclear, they can still be used as biomarkers of
arterial dysfunction [25].
IMT was significantly increased in EH patients, but
did not differ between SLE patients and healthy con-
trols. As our SLE patients did have decreased SAE with-
out having an increased IMT, we suggest that SAE is
already decreased prior to intima media thickening. Pre-
vious studies showed an increased IMT in SLE patients
[3,4,26]. Discordance between this study and previous
studies might be due to differences in age, disease dura-
tion and selection for patients without CVD. However,
IMT values of our patients closely resemble those found
by Roman et al in one of the largest studies to date on
atherosclerosis in SLE [5]. Their SLE patients even had
a decreased IMT compared to matched controls while
patients had significantly more carotid plaques. This
indicates that IMT, although considered a reliable mar-
ker for diffuse atherosclerosis, might not be a sensitive
marker for localised atherosclerotic lesions. To decrease
the possibility of missing localised atherosclerotic lesions
we measured IMT at six different segments and in addi-
tion to mean IMT we also calculated the maximum
IMT; however, no differences were found between SLE
patients and controls.
Multivariate analysis revealed that SLE is an indepen-
dent predictor of decreased SAE. Several disease-related
factors might be involved, including chronic inflamma-
tion. Levels of CRP were increased in our SLE patients,
even though the disease was inactive. Moreover, CRP
inversely correlated with SAE, suggesting that inflamma-
tion contributes to vascular dysfunction. This finding is
in accordance with several other studies reporting rela-
tions between CRP and indices of vascular function
[27-29]. It has been suggested that CRP itself contri-
butes to the development of atherosclerosis, as it exerts
direct proinflammatory effects on endothelial cells [30].
However, a recent study shows that polymorphisms in
the CRP gene, leading to increased CRP levels, are not
associated with an increased risk of vascular disease
[31]. Therefore, the role of CRP as causal factor in the
development of atherosclerosis remains controversial.
The positive correlation between creatinine clearance
and SAE suggests that renal function is also involved in
vascular dysfunction and atherogenesis. This is further
supported by the inverse correlation we found between
IMT and creatinine clearance in SLE patients (data not
shown). There is growing evidence that relatively minor
renal abnormalities such as a slightly reduced GFR or
microalbuminuria, even within the normal range, may be
associated with increased risk of CVD. One of the princi-
pal pathophysiological mechanisms that have been
proposed to link renal insufficiency to atherosclerosis is
EC dysfunction caused by dyslipidemia, increased blood
pressure, oxidative stress and low grade inflammation [32].
Oxidative stress and low grade inflammation, together
with decreased clearance of AGE precursors, might lead
to increased formation and accumulation of AGEs. AGEs
are a class of compounds resulting from non-enzymatic
glycation of proteins, lipids or nucleic acids under influ-
ence of oxidative stress. AGEs accumulate continuously
on long-lived proteins with aging, and are present in
inflamed tissue, such as rheumatoid synovia and athero-
sclerotic blood vessels [33]. We confirmed our previous
findings that AGE accumulation is increased in non-
lesional skin of SLE patients [6] and found that AGE
accumulation is inversely related to SAE. Three general
mechanisms may explain this relation. First, the cross-
linking of AGEs with proteins in the extracellular matrix
results in a decrease of blood vessel elasticity. Second,
intracellular AGE formation may alter cellular function.
Third, AGEs may modulate the function of cells by inter-
action with and activation of the receptor for AGEs
(RAGE) and other receptors [34].
Conclusions
In conclusion, vascular dysfunction, as shown by
decreased SAE, is present in quiescent SLE patients
without atherosclerosis. This decrease is independent of
traditional cardiovascular risk factors, but is related to
the presence of SLE. Disease related factors, such as
inflammation, impaired renal function and accumulation
of AGEs might be contributing to this vascular dysfunc-
tion. Measurement of SAE seems a clinically applicable
method to detect early vascular changes in SLE.
Nienhuis et al. Arthritis Research & Therapy 2010, 12:R181
http://arthritis-research.com/content/12/5/R181
Page 6 of 8Abbreviations
ACR: American College of Rheumatology; ACE: angiotensin converting enzyme;
AF: autofluorescence; AGEs: advanced glycation end products; AU: arbitrary
units; BMI: body mass index; BP: blood pressure; CCA: Common Carotid Artery;
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